van der Klauw M M, Wilson J H, Stricker B H
Drug Safety Unit, Inspectorate for Health Care, Rijswijk, The Netherlands.
Am J Hematol. 1998 Mar;57(3):206-11. doi: 10.1002/(sici)1096-8652(199803)57:3<206::aid-ajh4>3.0.co;2-z.
In this descriptive study, all 425 reports were included concerning drug-associated agranulocytosis as registered between 1974 and 1994 in the files of the Drug Safety Unit of the Dutch Inspectorate for Health Care. All reports were analysed as to the probability of agranulocytosis or neutropenia according to previously defined criteria. Subsequently, the causal relationship between exposure and outcome was assessed. It concerned 149 men and 271 women. One hundred and twelve reports were unclassifiable because age, gender, or total number of leukocytes at the time of reaction were unknown. In 100 reports agranulocytosis was probable, in 78 possible, in 8 reports neutropenia was probable, in 20 reports neutropenia was possible, and in 107 reports agranulocytosis or neutropenia were unlikely. In the 13 reports of probable agranulocytosis or neutropenia with a certain causal relationship, causative drugs were cimetidine, dipyrone, sulphasalazine, methyldopa, spironolactone, propylthiouracil (2), thiamazole, sulphamethoxazole with trimethoprim, gentamicin, a combination preparation containing aminophenazone, benzylpenicillin and indomethacin. The individual drugs most often reported to cause agranulocytosis or neutropenia were: dipyrone (19), mianserin (15), sulphasalazine (13), sulphamethoxazole with trimethoprim (11), the group of penicillins (9), cimetidine (8), the thiouracil derivatives (8), phenylbutazone (8), and penicillamine (8). Agranulocytosis is a serious and fairly frequently reported adverse reaction. The reporting system of the Drug Safety Unit can be used very well for signal generation concerning adverse reactions to drugs.
在这项描述性研究中,纳入了荷兰医疗保健检查局药物安全部门1974年至1994年档案中登记的所有425份与药物相关的粒细胞缺乏症报告。根据先前定义的标准,对所有报告进行粒细胞缺乏症或中性粒细胞减少症可能性分析。随后,评估暴露与结果之间的因果关系。研究涉及149名男性和271名女性。112份报告无法分类,因为反应时的年龄、性别或白细胞总数未知。100份报告可能为粒细胞缺乏症,78份可能为粒细胞缺乏症,8份报告中性粒细胞减少症可能,20份报告中性粒细胞减少症可能,107份报告粒细胞缺乏症或中性粒细胞减少症不太可能。在13份可能的粒细胞缺乏症或中性粒细胞减少症且有明确因果关系的报告中,致病药物为西咪替丁、安乃近、柳氮磺胺吡啶、甲基多巴、螺内酯、丙硫氧嘧啶(2例)、甲巯咪唑、复方磺胺甲恶唑、庆大霉素、含氨基比林、苄青霉素和吲哚美辛的复方制剂。最常报告导致粒细胞缺乏症或中性粒细胞减少症的个别药物为:安乃近(19例)、米安色林(15例)、柳氮磺胺吡啶(13例)、复方磺胺甲恶唑(11例)、青霉素类(9例)、西咪替丁(8例)、硫脲衍生物(8例)、保泰松(8例)和青霉胺(8例)。粒细胞缺乏症是一种严重且报告频率相当高的不良反应。药物安全部门的报告系统可很好地用于产生有关药物不良反应的信号。